Catalyst's Firdapse gets Priority Review in U.S.

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) said FDA accepted and granted Priority Review to

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE